Peter Adamson
About
In The Last Decade
Peter Adamson
99 papers receiving 5.6k citations
Peers
Comparison fields: 5 of 125
- Molecular Biology 2.9k
- Ophthalmology 977
- Immunology 946
- Immunology and Allergy 922
- Cell Biology 808
Countries citing papers authored by Peter Adamson
This map shows the geographic impact of Peter Adamson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Adamson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Adamson more than expected).
Fields of papers citing papers by Peter Adamson
This network shows the impact of papers produced by Peter Adamson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Adamson. The network helps show where Peter Adamson may publish in the future.
Co-authorship network of co-authors of Peter Adamson
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Adamson. A scholar is included among the top collaborators of Peter Adamson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Adamson. Peter Adamson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Allele specific knock-down of human P23H rhodopsin mRNA and prevention of retinal degeneration in humanized P23H rhodopsin knock-in mouse, following treatment with an intravitreal GAPmer antisense oligonucleotide (QR-1123) | 5 |
| 2 | QR-421a, an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations | 8 |
| 3 | 44 | |
| 4 | 74 | |
| 5 | Antisense Oligonucleotide-induced Skipping of USH2A exon13 Restores Visual Function in Zebrafish | 2 |
| 6 | QR-110 Treatment for Leber’s Congenital Amaurosis Type 10: Restoration of CEP290 mRNA Levels and Ciliation in LCA10 iPSC-Derived Optic Cups | 1 |
| 7 | Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies | 5 |
| 8 | Lp-PLA 2 is a potential therapeutic target in diabetic macula edema | 2 |
| 9 | 60 | |
| 10 | 24 | |
| 11 | 59 | |
| 12 | 115 | |
| 13 | 96 | |
| 14 | 21 | |
| 15 | 10 | |
| 16 | 254 | |
| 17 | Genetically engineered human retinal pigment epithelial cells for intraocular transplantation therapy. | 2 |
| 18 | Grafting SV40 transformed rat retinal epithelial cells to the sub-retinal space | 4 |
| 19 | 12 | |
| 20 | 17 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.